R&D News | pharmaphorum

News

BMS’ Opdivo fails late-stage brain cancer test

Bristol-Myers Squibb has run into yet another hurdle trying to extend the use of its immuno-oncology blockbuster Opdivo into new types of cancer.

News

AstraZeneca shows cardiovascular safety for roxadustat

AstraZeneca has announced that pooled analyses of the phase III trials for its kidney disease drug roxadustat confirm the drug’s cardiovascular safety – a good sign for the potential blockb

News

Biotech Verve launches on mission to replace statins with CR...

Could CRISPR gene editing one day replace the need for cholesterol-lowering drugs such as statins?

News

Pfizer acquires Therachon and its dwarfism drug

Pfizer has announced it will pay $340 million upfront to snap up rare disease biotech Therachon, which is developing treatments for a form

News

Pfizer claims FDA okay for rare heart disease drug tafamidis

The FDA has given a green light to two formulations of Pfizer’s tafamidis that have become the first drugs to be approved in the US for cardiomyopathy associated with rare disease transthyr

News

Trial could unlock asthma use for GSK’s Trelegy

GlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple of years and has new data that could open up a new market.

BMS’ Opdivo fails late-stage brain cancer test

AstraZeneca shows cardiovascular safety for roxadustat

Biotech Verve launches on mission to replace statins with CR...

Pfizer acquires Therachon and its dwarfism drug

Pfizer claims FDA okay for rare heart disease drug tafamidis

Trial could unlock asthma use for GSK’s Trelegy

Electra sets terms for IPO, hoping to raise up to $347m

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks